All In Biotech

Drug Trial Radar · NCT07076121

A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)

A Randomized, Phase 2/3 Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma Harboring Homozygous MTAP Deletion

Last checked: Nov 20, 2026Latest source record: Jun 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 470 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

470

Planned (sponsor's estimate)

Start

Oct 23, 2025

Primary completion

May 3, 2029

Study completion May 3, 2029

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Jul 21, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety and efficacy of Navlimetostat (BMS-986504), a selective, MTA-cooperative PRMT5 inhibitor, in combination with Nab-paclitaxel/Gemcitabine (nab-p/gem) versus placebo in combination with nab-p/gem, in participants with untreated metastatic Pancreatic Ductal Adenocarcinoma (PDAC) with homozygous methylthioadenosine phosphorylase (MTAP) deletion.

Conditions

  • Pancreatic Ductal Adenocarcinoma

Interventions

  • NavlimetostatDrug

    Specified dose on specified days

  • GemcitabineDrug

    Specified dose on specified days

  • Nab-paclitaxelDrug

    Specified dose on specified days

  • PlaceboDrug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival as assessed by Response Evaluation Criteria in Solid Tumors version v1.1 (RECIST v1.1)Time frame: Up to 3 years after last participant is randomized
  2. Overall Survival (OS)Time frame: Up to 3 years after last participant is randomized

Locations

269 sites in 36 countries. Site status is shown where the registry gives one.

  • Mayo Clinic in Arizona - Phoenix

    Phoenix, Arizona

  • Local Institution - 0365

    Tucson, Arizona

  • Highlands Oncology Group

    Springdale, Arkansas

  • Scripps Green Hospital

    La Jolla, California

  • Local Institution - 0157

    San Francisco, California

  • Baptist MD Anderson Cancer Center

    Jacksonville, Florida

  • Mayo Clinic in Florida

    Jacksonville, Florida

  • Winship Cancer Institute, Emory University

    Atlanta, Georgia

  • Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital

    Marietta, Georgia

  • St. Luke's Cancer Institute: Boise

    Boise, Idaho

  • Local Institution - 0168

    Chicago, Illinois

  • Local Institution - 0125

    Westwood, Kansas

  • Local Institution - 0370

    Louisville, Kentucky

  • Local Institution - 0371

    Baltimore, Maryland

  • Johns Hopkins Hospital

    Baltimore, Maryland

  • Local Institution - 0120

    Boston, Massachusetts

  • Brigitte Harris Cancer Pavilion

    Detroit, Michigan

  • The Cancer & Hematology Centers

    Grand Rapids, Michigan

  • Mayo Clinic in Rochester, Minnesota

    Rochester, Minnesota

  • University Of Nebraska Medical Center

    Omaha, Nebraska

  • Roswell Park Cancer Institute

    Buffalo, New York

  • Northwell Health/ RJ Zuckerberg Cancer Center

    Lake Success, New York

  • Laura and Isaac Perlmutter Cancer Center at NYU Langone

    Mineola, New York

  • NYU Winthrop Hospital

    Mineola, New York

  • Icahn School of Medicine at Mount Sinai

    New York, New York

  • Local Institution - 0279

    New York, New York

  • Wilmot Cancer Institute

    Rochester, New York

  • University of North Carolina Medical Center

    Chapel Hill, North Carolina

  • Local Institution - 0376

    Columbus, Ohio

  • Kaiser Permanente Center for Health Research

    Portland, Oregon

  • Local Institution - 0162

    Portland, Oregon

  • St. Luke's University Health Network

    Bethlehem, Pennsylvania

  • Local Institution - 0301

    Lancaster, Pennsylvania

  • Thomas Jefferson University - Medical Oncology

    Philadelphia, Pennsylvania

  • Local Institution - 0368

    Pittsburgh, Pennsylvania

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania

  • SCRI Oncology Partners

    Nashville, Tennessee

  • Tennessee Oncology, PLLC

    Smyrna, Tennessee

  • Texas Oncology - DFW

    Dallas, Texas

  • Uus Oncology

    Fort Worth, Texas

Showing 40 of 269 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.